Veru Inc. Reports Improved Net Loss of $6.99 Million for Q2 2026

Veru Inc. reported a net loss of $6.99 million for the three months ended June 30, 2026, a slight improvement from a net loss of $7.33 million during the same period in 2025. For the nine months ending June 30, 2026, the company recorded a net loss of $15.06 million, compared to a net loss of $24.18 million in the prior year. The company’s total operating expenses decreased to $7.71 million in the latest quarter from $8.03 million a year earlier, primarily due to reduced general and administrative costs. Research and development expenses increased to $4.35 million from $3.02 million, reflecting ongoing investments in the Phase 2b PLATEAU clinical study for enobosarm, a drug aimed at enhancing weight loss in patients receiving GLP-1 receptor agonists.

In terms of financial position, Veru's cash, cash equivalents, and restricted cash rose to $23.88 million as of June 30, 2026, up from $15.79 million at the end of the previous fiscal year. The increase in cash was attributed to a successful public offering completed in October 2025, which generated approximately $23.4 million in net proceeds. The company’s working capital also improved to $21.1 million from $11.1 million, bolstered by a decrease in accounts payable and accrued expenses.

Strategically, Veru has made significant moves, including the completion of the Phase 2b PLATEAU clinical trial enrollment, which evaluates the combination of enobosarm with Novo Nordisk’s Wegovy for weight management in older adults. The company has also entered a clinical supply agreement with Novo Nordisk, which will provide Wegovy at no charge for the study. Additionally, Veru has been active in enhancing its intellectual property portfolio, receiving a Notice of Allowance for a patent application related to enobosarm, which is expected to provide protection until at least 2046.

Operationally, Veru has shifted its focus following the sale of its FC2 business in December 2024, which has allowed the company to concentrate on its drug development programs. The company has no revenues from continuing operations, as it has transitioned away from its previous commercial products. The ongoing clinical trials and strategic partnerships are expected to be critical in driving future growth. However, the company has expressed concerns regarding its ability to continue as a going concern, citing the need for substantial capital to support its drug development efforts and the uncertainty surrounding future financing.

Looking ahead, Veru anticipates continued investment in its research and development initiatives, particularly for enobosarm and sabizabulin, as it seeks to address significant unmet medical needs in obesity and cardiovascular disease. The company is also exploring potential pathways for regulatory approval based on recent FDA feedback, which could shape its clinical development strategy moving forward.